Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 4/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439028 | 0.83 | MAPK1 (0.59) | MEN1KMT2ATSHRGABRA5MAPT | |
| SCHEMBL14480242 | 0.83 | L3MBTL1 (0.43) | KMT2AHPGDSMN1; SMN2HCAR3MAPT | |
| SCHEMBL31003231 | 0.83 | L3MBTL1 (0.43) | KMT2AHPGDSMN1; SMN2HCAR3MAPT | |
| SCHEMBL27535791 | 0.82 | P4HTM (0.57) | MEN1AHRKMT2AP4HTM | |
| SCHEMBL1680993 | 0.81 | MAPT (0.53) | HPGDHCAR3GABRA5MAPTP4HTM | |
| SCHEMBL13043365 | 0.81 | PLK1 (0.55) | BAZ2BPLK1GRM5HPGDTSHR | |
| SCHEMBL9566760 | 0.81 | RAB9A (0.60) | MEN1AHRKMT2AGABRA5P4HTM | |
| SCHEMBL31480792 | 0.80 | NNMT (0.57) | HPGDSSMN1; SMN2MKNK1MKNK2GABRA5 | |
| SCHEMBL2818852 | 0.80 | MAPT (0.51) | HPGDHCAR3GABRA5MAPTP4HTM | |
| SCHEMBL28012424 | 0.80 | SCN9A (0.56) | MEN1KMT2AGABRA5HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969389-B2 | Substituted 6-methylnicotinamides as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20110294858-A1 | SUBSTITUTED 6-METHYLNICOTINAMIDES AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-12-01 | — | — | US | disclosed |
| US-7553845-B2 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2009-06-30 | — | — | US | disclosed |
| US-7553845-B2 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2009-06-30 | — | — | US | disclosed |
| US-7553845-B2 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2009-06-30 | — | — | US | disclosed |
| US-20060199962-A1 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2006-09-07 | — | — | US | disclosed |
| EP-1664047-A1 | SUBSTITUTED INDOLIZINE 1,2,3,6,7,8 DERIVATIVES, FGFS INHIBITORS, A METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028476-A1 | SUBSTITUTED INDOLIZINE 1,2,3,6,7,8 DERIVATIVES, FGFS INHIBITORS, A METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI-AVENTIS (FR) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294858-A1 | SUBSTITUTED 6-METHYLNICOTINAMIDES AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM6 | BAZ2B 2271/4885PLK1 3178/4885HPGDS 4533/4885 |
| US-20060199962-A1 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | FGF1, FGF2, FGFR1 | BAZ2B 2283/4885PLK1 234/4885HPGDS 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.